News | 26 September 2024
Pfizer withdraws all lots of sickle cell disease treatment voxelotor
Pfizer's decision is based on the totality of clinical data
Pfizer's decision is based on the totality of clinical data
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
NMC to continue its efforts to improve and enhance the quality of medical education in the country
Focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
This office will be the central hub for all operations related to companies ethical pharmaceutical business
This approval reflects company’s unwavering commitment that the quality assurance
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
Stable profits, low leverage to keep credit profiles comfortable
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Fermenta Biotech’s API manufacturing facility receives EU GMP compliance certificate
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Coupled with Shea Butter, Cocoa Butter, and Mango Butter, the balm provides deep hydration, ensuring lips remain soft, smooth, and well-moisturized throughout the day
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
Subscribe To Our Newsletter & Stay Updated
